BofA Securities Likes BioMarin (BMRN) Risk/Reward Into Data
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $89.49 --0%
Rating Summary:
23 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 13
Rating Summary:
23 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 13
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham reiterated a Buy rating and $90.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), saying he likes the risk/reward into "imminent" vosoritide phase 3 data.
Meacham said positive data could shift the story away from data nuances. The vosoritide data is expected by year end with approval in 2021.
For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.
Shares of BioMarin Pharmaceutical Inc. closed at $79.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northwest Bancshares, Inc. (NWBI) PT Lowered to $10 at Piper Sandler
- AZZ Inc. (AZZ) PT Raised to $85 at B.Riley
- Adriatic Metals PLC (ADT1:LN) PT Raised to GBP2.75 at Stifel
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
